Home >> Research Area >> Enrofloxacin

Enrofloxacin

CAS# 93106-60-6

Enrofloxacin

2D Structure

Catalog No. BCC4657----Order now to get a substantial discount!

Product Name & Size Price Stock
Enrofloxacin: 5mg $17 In Stock
Enrofloxacin: 10mg Please Inquire In Stock
Enrofloxacin: 20mg Please Inquire Please Inquire
Enrofloxacin: 50mg Please Inquire Please Inquire
Enrofloxacin: 100mg Please Inquire Please Inquire
Enrofloxacin: 200mg Please Inquire Please Inquire
Enrofloxacin: 500mg Please Inquire Please Inquire
Enrofloxacin: 1000mg Please Inquire Please Inquire
Related Products
  • MLN8237 (Alisertib)

    Catalog No.:BCC2166
    CAS No.:1028486-01-2
  • CCT137690

    Catalog No.:BCC2188
    CAS No.:1095382-05-0
  • CYC116

    Catalog No.:BCC2181
    CAS No.:693228-63-6
  • MLN8054

    Catalog No.:BCC2170
    CAS No.:869363-13-3
  • TAK-901

    Catalog No.:BCC2180
    CAS No.:934541-31-8
  • PF-03814735

    Catalog No.:BCC2184
    CAS No.:942487-16-3

Quality Control of Enrofloxacin

3D structure

Package In Stock

Enrofloxacin

Number of papers citing our products

Chemical Properties of Enrofloxacin

Cas No. 93106-60-6 SDF Download SDF
PubChem ID 71188 Appearance Powder
Formula C19H22FN3O3 M.Wt 359.39
Type of Compound N/A Storage Desiccate at -20°C
Synonyms BAY-Vp2674; PD160788
Solubility DMSO : 10 mg/mL (27.82 mM; Need ultrasonic)
H2O : 1 mg/mL (2.78 mM; ultrasonic and warming and heat to 80°C)
Chemical Name 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid
SMILES CCN1CCN(CC1)c2cc3N(C=C(C(O)=O)C(=O)c3cc2F)C4CC4
Standard InChIKey SPFYMRJSYKOXGV-UHFFFAOYSA-N
Standard InChI InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Enrofloxacin

DescriptionEnrofloxacin is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.In Vitro:Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL[1].In Vivo:Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment[2].

References:
[1]. Sulyok KM, et al.Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe. BMC Vet Res. 2014 Oct 25;10:256. [2]. Hetze S, et al. Superiority of preventive antibiotic treatment compared with standard treatment of poststroke pneumonia in experimental stroke: a bed to bench approach. J Cereb Blood Flow Metab. 2013 Jun;33(6):846-54.

Protocol

Animal Administration [2]
Mice[2] 11- to 14-week-old C57Bl6/J male mice are used. Enrofloxacin (2.5% oral solution) is dispensed in saline (2 mg/mL), antibiotic-treated animals receive a daily orally dispensed dose of 10 mg/kg body weight via feeding needle every 12 hours over a period of 7 days, while placebo animals receive the same amount of saline via feeding needle. Animals of preventive antibiotic group obtained Enrofloxacin after waking from reperfusion anesthesia (ca. 1 hour after operation). Therapeutic antibiotic treatment is given immediately after appearance of clinical signs (general health score>5) and confirmation of lung infection by MRI (signal rate≥5%). The group allocation is randomized[2].

References:
[1]. Sulyok KM, et al.Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe. BMC Vet Res. 2014 Oct 25;10:256. [2]. Hetze S, et al. Superiority of preventive antibiotic treatment compared with standard treatment of poststroke pneumonia in experimental stroke: a bed to bench approach. J Cereb Blood Flow Metab. 2013 Jun;33(6):846-54.

Enrofloxacin Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Enrofloxacin Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Enrofloxacin

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.7825 mL 13.9125 mL 27.8249 mL 55.6499 mL 69.5623 mL
5 mM 0.5565 mL 2.7825 mL 5.565 mL 11.13 mL 13.9125 mL
10 mM 0.2782 mL 1.3912 mL 2.7825 mL 5.565 mL 6.9562 mL
50 mM 0.0556 mL 0.2782 mL 0.5565 mL 1.113 mL 1.3912 mL
100 mM 0.0278 mL 0.1391 mL 0.2782 mL 0.5565 mL 0.6956 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Enrofloxacin

Enrofloxacin is a fluoroquinolone antibiotic.

Featured Products
New Products
 

References on Enrofloxacin

PHARMACOKINETICS OF A SINGLE DOSE OF ORAL AND SUBCUTANEOUS ENROFLOXACIN IN CARIBBEAN FLAMINGOS (PHOENICOPTERUS RUBER RUBER).[Pubmed:28363047]

J Zoo Wildl Med. 2017 Mar;48(1):72-79.

Enrofloxacin is a fluoroquinolone antimicrobial that is widely used in veterinary medicine because of its bactericidal activity and safety in a broad range of species. Caribbean flamingos, a member of the order Phoenicopteriformes, are popular in zoological collections and suffer from a variety of conditions that can result from or lead to bacterial infection. In this study, two groups of 7 adult captive Caribbean flamingos received a single dose of 15 mg/kg Enrofloxacin, administered either orally or subcutaneously. Plasma concentrations of Enrofloxacin and its metabolite, ciprofloxacin, were measured using liquid chromatography and mass spectrometry. Pharmacokinetic analysis was performed using noncompartmental methods. The pharmacokinetic parameters for both routes of administration were similar, with a mean peak plasma concentration (Cmax) of 5.25 and 5.77 mug/ml, a mean time to peak plasma concentration (Tmax) of 1.49 and 1.1 hr, a mean area under the curve (AUC) of 49.9 and 47.3 hr.mug/ml, and a mean terminal half-life (t1/2) of 5.83 and 6.46 hr for oral and subcutaneous dosing, respectively. Conversion to ciprofloxacin was minimal, with the AUC of ciprofloxacin representing <3% of the Enrofloxacin AUC for both routes of administration. Based on the results of the present study, a dose of 15 mg/kg Enrofloxacin delivered either orally or subcutaneously in the Caribbean flamingo every 24 hr is recommended for susceptible bacterial pathogens with a minimal inhibitory concentration

Ecotoxicity of veterinary enrofloxacin and ciprofloxacin antibiotics on anuran amphibian larvae.[Pubmed:28233700]

Environ Toxicol Pharmacol. 2017 Apr;51:114-123.

The ecological risks posed by two beta-diketone antibiotics (DKAs, Enrofloxacin, ENR and ciprofloxacin, CPX), characterized by their long persistence in aqueous environments and known deleterious effect on model organisms such as zebrafish were analysed using Rhinella arenarum larvae. Sublethal tests were conducted using environmentally relevant concentrations of both ENR and CPX (1-1000mugL(-1)) under standard laboratory conditions for 96h. Biological endpoints and biomarkers evaluated were body size, shape, development and growth rates, and antioxidant enzymes (glutathione-S-transferase, GST; Catalase, CAT). Risk assessment was analysed based on ration quotients (RQ). The size and shape measurements of the larvae exposed to concentrations greater than 10mugL(-1) of CPX were lower compared to controls (Dunnett post hoc p<0.05) and presented signs of emaciation. Concentrations of 1000mugL(-1)of CPX induced GST activity, in contrast with inhibited GST and CAT of larvae exposed to ENR. Risk assessments indicated that concentrations greater than or equal to10mugL(-1) of CPX and ENR are ecotoxic for development, growth, detoxifying, and oxidative stress enzymes. It is suggested that additional risk assessments may provide evidence of bioaccumulation of CPX and ENR in tissues or organs of amphibian larvae by mesocosm sediment test conditions. Finally, intestinal microbiome studies should be considered to establish the mechanisms of action of both antibiotics.

Description

Enrofloxacin (BAY Vp 2674) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.

Keywords:

Enrofloxacin,93106-60-6,BAY-Vp2674; PD160788,Natural Products, buy Enrofloxacin , Enrofloxacin supplier , purchase Enrofloxacin , Enrofloxacin cost , Enrofloxacin manufacturer , order Enrofloxacin , high purity Enrofloxacin

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: